A new class of opioid withdrawal treatment emerges in The Sparrow Therapy System — the first clinically proven, drug-free, needle-free, wearable neurostimulation solution for opioid withdrawal relief

Breakthrough Designation Helps Advance the Therapy Targeting a Significant Unmet Need in the Treatment of Neonatal Opioid Withdrawal Syndrome

Spark Biomedical, Inc, CARMAhealth, and Recovery Unplugged jointly developed abstract places second in the American Society of Pain and Neuroscience (ASPN) 2020 Annual Conference. The abstract entitled, Interim Results from a Randomized, Double-Blind, Controlled Trial Examining Use of Transcutaneous Auricular Neurostimulation (tAN) to Improve Symptoms Associated with Opioid Withdrawal, outlines initial results from the first 20 patients in the clinical trial targeting participants with opioid use disorder.

Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal relief — announces the official formation of the company’s Medical Advisory Board on Pain Management.

While instances of Neonatal Opioid Withdrawal Syndrome (NOWS) are still on the rise, and the eyes of the nation remain focused on a pandemic, the Medical University of South Carolina (MUSC) and Spark Biomedical, Inc. are tackling opioid withdrawal in newborns — the most innocent victims of the still-looming opioid crisis. This groundbreaking clinical trial pairs Spark’s Transcutaneous Auricular Neurostimulation (tAN™) device for newborns — the Roo — with the pediatric neurostimulation expertise and facilities of MUSC to develop a safe and more effective withdrawal relief solution for NOWS.

The highlight of the 2020 NANS session was a competition among 12 new and emerging firms in the neuromodulation industry. Each entrepreneur was give 10 minutes to present and then field questions from the judges and the audience in an effort to win cash prizes and “Best in Show.”

We invite you to join Spark Biomedical, Inc. as we present and exhibit at the North American Neuromodulation Society 23rd Annual Conference, Las Vegas, NV at Caesar’s Palace.

Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, today announced open patient enrollment in their clinical trial to validate the company’s auricular neurostimulation device for opioid withdrawal relief — currently named “Phoenix.” Spark is partnering with CARMAhealth a collaborative primary care and psychiatric outpatient practice with a specialty focus on addiction medicine and Recovery Unplugged. Patients with opioid use disorder (OUD) will enroll in the trial at two Recovery Unplugged locations in Austin, Texas, and Lake Worth, Florida.

FUNDS TO VALIDATE TRANSCUTANEOUS AURICULAR NEUROSTIMULATION FOR RELIEVING WITHDRAWAL SYMPTOMS IN INFANTS BORN WITH NEONATAL ABSTINENCE SYNDROME (NAS) Dallas, TX, October 18, 2019 — Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative. The grant (1R43DA050360-01) will be used to validate the use of neurostimulation to relieve withdrawal symptoms in infants born with neonatal abstinence syndrome (NAS).

A Texas A&M University former student’s startup, Spark Biomedical, was awarded $50,000 as the winner of the 2019 Texas A&M New Ventures Competition (TNVC) hosted by the Texas A&M Engineering Experiment Station (TEES). Daniel Powell is CEO of the medical device company, which is developing noninvasive neurostimulation solutions for opioid withdrawal and addiction.